+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anavex Life Sciences Corp - logo

Anavex Life Sciences is a biopharmaceutical company that develops differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat diseases of the central nervous system, pain and various types of cancer. The company's best known product is ANAVEXTM 2-73, a compound being developed to treat Alzheimer's disease, Parkinson's disease and related diseases. The company was founded in 2006 and is based in New York.

Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Schizophrenia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 295 Pages
  • Global
From
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 1663 Pages
  • Global
From
Alzheimer's Drugs Global Market Report 2024 - Product Thumbnail Image

Alzheimer's Drugs Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Fragile X Syndrome Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update - Product Thumbnail Image

Fragile X Syndrome Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update

  • Report
  • February 2023
  • 92 Pages
  • Global
From
Parkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Parkinson's Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • September 2022
  • 1079 Pages
  • Global
From
Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Rett Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 110 Pages
  • Global
From
Fragile X Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Fragile X Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • June 2022
  • 126 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M2 (CHRM2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • May 2022
  • 61 Pages
  • Global
From
Global Dementia Drugs Market by Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia), Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors) - Forecast 2024-2030 - Product Thumbnail Image

Global Dementia Drugs Market by Indications (Alzheimer's Disease, Lewy Body Dementia, Parkinsons Disease Dementia), Drug Class (Cholinesterase Inhibitors, Glutamate Inhibitors, MAO Inhibitors) - Forecast 2024-2030

  • Report
  • March 2024
  • 187 Pages
  • Global
From
Global Infantile Spasms Therapeutics Market by Dosage (Liquid, Solid), Route of Administration (Oral, Parental) - Forecast 2024-2030 - Product Thumbnail Image

Global Infantile Spasms Therapeutics Market by Dosage (Liquid, Solid), Route of Administration (Oral, Parental) - Forecast 2024-2030

  • Report
  • March 2024
  • 180 Pages
  • Global
From
Global Infantile Spasms Therapeutics Market 2024-2028 - Product Thumbnail Image

Global Infantile Spasms Therapeutics Market 2024-2028

  • Report
  • December 2023
  • 154 Pages
  • Global
From
Alzheimer's Disease - Pipeline Review, H2 2020 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H2 2020

  • Drug Pipelines
  • August 2020
  • 1785 Pages
  • Global
From
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 3237 Pages
  • Global
From
Epilepsy (Central Nervous System) - Drugs In Development, 2021 - Product Thumbnail Image

Epilepsy (Central Nervous System) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 789 Pages
  • Global
From
Dementia (Central Nervous System) - Drugs In Development, 2021 - Product Thumbnail Image

Dementia (Central Nervous System) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 682 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drugs In Development, 2021 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drugs In Development, 2021

  • Drug Pipelines
  • June 2021
  • 96 Pages
  • Global
From
Muscarinic Acetylcholine Receptor Global Market Report 2024 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Neuropathic Pain - Pipeline Review, H2 2019 - Product Thumbnail Image

Neuropathic Pain - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 838 Pages
  • Global
From
Prostate Cancer - Pipeline Review, H2 2020 - Product Thumbnail Image

Prostate Cancer - Pipeline Review, H2 2020

  • Drug Pipelines
  • November 2020
  • 3323 Pages
  • Global
From
Rett Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Rett Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • February 2024
  • 60 Pages
  • Global
From
Loading Indicator